Mahesh Hegde
Overview
Explore the profile of Mahesh Hegde including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
577
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hegde M, Ahmad M, Mulet Lazaro R, Sugita M, Li R, Hu K, et al.
Leukemia
. 2024 Nov;
39(2):360-370.
PMID: 39572712
Oncogenic programs regulate the proliferation and maintenance of cancer stem cells, and can define pharmacologic dependencies. In acute myeloid leukemia (AML) with the chromosome inversion 16 (inv(16)), the fusion oncoprotein ...
2.
Ahmad M, Hegde M, Wong W, Mohammadhosseini M, Garrett L, Carrascoso A, et al.
Blood Adv
. 2023 Sep;
7(23):7304-7318.
PMID: 37756546
Germ line mutations in the RUNX1 gene cause familial platelet disorder (FPD), an inherited disease associated with lifetime risk to hematopoietic malignancies (HM). Patients with FPD frequently show clonal expansion...
3.
Pulikkan J, Hegde M, Ahmad H, Belaghzal H, Illendula A, Yu J, et al.
Cell
. 2018 Aug;
174(5):1325.
PMID: 30142347
No abstract available.
4.
Pulikkan J, Hegde M, Ahmad H, Belaghzal H, Illendula A, Yu J, et al.
Cell
. 2018 Jun;
174(1):172-186.e21.
PMID: 29958106
The fusion oncoprotein CBFβ-SMMHC, expressed in leukemia cases with chromosome 16 inversion, drives leukemia development and maintenance by altering the activity of the transcription factor RUNX1. Here, we demonstrate that...
5.
Hegde M, Vartak S, Kavitha C, Ananda H, Prasanna D, Gopalakrishnan V, et al.
Sci Rep
. 2017 Jun;
7(1):2533.
PMID: 28566733
Chemically synthesized small molecules play important role in anticancer therapy. Several chemical compounds have been reported to damage the DNA, either directly or indirectly slowing down the cancer cell progression...
6.
Ananda H, Sharath Kumar K, Nishana M, Hegde M, Srivastava M, Byregowda R, et al.
Mol Cell Biochem
. 2016 Nov;
426(1-2):149-160.
PMID: 27882441
Pyrazole moiety represents an important category of heterocyclic compound in pharmaceutical and medicinal chemistry. The novel 1-aryl-3, 5-bis (het) aryl pyrazole derivatives were synthesized with complementary regioselectivity. The chemical structures...
7.
Thomas E, Gopalakrishnan V, Hegde M, Kumar S, Karki S, Raghavan S, et al.
Sci Rep
. 2016 Oct;
6:34653.
PMID: 27748367
Resveratrol is one of the most widely studied bioactive plant polyphenols which possesses anticancer properties. Previously we have reported synthesis, characterization and identification of a novel resveratrol analog, SS28. In...
8.
Vartak S, Hegde M, Iyer D, Gaikwad S, Gopalakrishnan V, Srivastava M, et al.
Biochem Pharmacol
. 2016 Oct;
122:10-22.
PMID: 27693384
Antiapoptotic protein BCL2, serves as an excellent target for anticancer therapy owing to its increased level in cancers. Previously, we have described characterization of a novel BCL2 inhibitor, Disarib, which...
9.
Ananda H, Sharath Kumar K, Hegde M, Rangappa K
Mol Cell Biochem
. 2016 Jul;
420(1-2):141-50.
PMID: 27473146
Isoxazole derivatives are an important group of chemotherapeutic prototypes. In the current study, we have synthesized few isoxazole derivatives and tested them for their antiproliferative properties in cancer cell lines...
10.
Iyer D, Vartak S, Mishra A, Goldsmith G, Kumar S, Srivastava M, et al.
FEBS J
. 2016 Jul;
283(18):3408-37.
PMID: 27444341
The antiapoptotic protein BCL2 is overexpressed in several cancers and contributes to prolonged cell survival and chemoresistance, lending itself as an excellent target for cancer therapy. Here, we report the...